They can provide relief but often come with serious side effects like infections, weight gain, mood swings, and bone loss
For combination research they're used together
Replacing the C-domain loop of IGF1 with a short GGGG loop completely abolishes its binding to IGF1R 19 (Fig
Oral BPC-157 We use the oral formulation primarily when trying to influence gut-specific healing, including: Stomach ulcers Gut wall permeability Crohns disease Ulcerative colitis Celiac disease Post-infectious diarrhea Microscopic colitis We may also consider oral BPC-157 when conditions appear to be influenced by gut inflammation, including psoriasis, rosacea, mood disorders, and cognitive changes
1-30C, away from light
Retatrutide's TRIUMPH-4 trial reported nausea in 38.1-43.2% of participants, dysesthesia in 8.8-20.9% (dose-dependent), and discontinuation rates of 12.2-18.2%